双阳性MPO/PR3 ANCA与血管炎:基于7例病例研究及人工智能辅助文献综述的见解
该研究在法国布雷斯特大学医院免疫实验室回顾性筛查2013年3月至2022年3月的双阳性MPO/PR3 ANCA(DP-ANCA)病例,并结合人工智能辅助与人工PubMed检索进行文献综述,共汇总103例DP-ANCA病例,识别出四种表型:特发性AAV约30%、药物诱导性AAV约25%、伴低血管炎风险的自身免疫病约20%、与AAV无关的免疫紊乱合并症约25%。作者认为约50%的DP-ANCA患者发生AAV(药物诱导或特发性),其余50%伴既存免疫失调者血管炎风险极低,提示该人群临床表现高度多样、需个体化诊疗。
要点
- DP-ANCA病例汇总共103例,识别出四种不同临床表型。
- 约50%的DP-ANCA患者发生AAV,包括药物诱导性和特发性形式。
- 其余约50%伴既存免疫失调状况者血管炎风险极低。
核心结论
- 对百余例DP-ANCA病例的分析提示其临床与免疫病理表现存在显著多样性。
- 约50%的DP-ANCA患者发生AAV(药物诱导或特发性),其余50%伴既存免疫失调状况者血管炎风险极低。
- 作者认为这些发现凸显DP-ANCA的复杂本质及其对患者健康影响的变异性,并强调此类病例需个体化诊断与管理策略。
研究设计与样本
- 在法国布雷斯特大学医院免疫实验室对2013年3月至2022年3月的ANCA结果进行DP-ANCA病例的回顾性筛查。
- 收集每例DP-ANCA病例的临床、生物学、影像学和组织学数据。
- 进行DP-ANCA的综合文献综述,结合使用BIBOT软件的人工智能检索与人工PubMed数据库检索。
- 本院7例病例报告与文献病例合计得到103例已描述的DP-ANCA患者病例。
主要发现
- 共识别出四种不同表型:特发性AAV约占30%。
- 药物诱导性AAV约占25%。
- 伴低血管炎风险的自身免疫病约占20%。
- 与AAV无关的免疫紊乱合并症(感染、肿瘤等)约占25%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV) are rare conditions characterized by inflammatory cell infiltration in small blood vessels, leading to tissue necrosis. While most patients with AAV present antibodies against either myeloperoxidase (MPO) or proteinase 3 (PR3), rare cases of dual positivity for both antibodies (DP-ANCA) have been reported, and their impact on the clinical picture remains unclear. The goal of this study was to investigate the clinical implications, phenotypic profiles and outcomes of patients with DP-ANCA. METHODS: A retrospective screening for DP-ANCA cases was conducted at Brest University Hospital's immunology laboratory (France), analysing ANCA results from March 2013 to March 2022. Clinical, biological, imaging, and histological data were collected for each DP-ANCA case. Additionally, a comprehensive literature review on DP-ANCA was performed, combining an artificial intelligence (AI)-based search using BIBOT software with a manual PUBMED database search. RESULTS: The report of our cases over the last 9 years and those from the literature yielded 103 described cases of patients with DP-ANCA. We identified four distinct phenotypic profiles: (i) idiopathic AAV (∼30%); (ii) drug-induced AAV (∼25%); (iii) autoimmune disease associated with a low risk of developing vasculitis (∼20%); and (iv) immune-disrupting comorbidities (infections, cancers, etc) not associated with AAV (∼25%). CONCLUSION: This analysis of over a hundred DP-ANCA cases suggests substantial diversity in clinical and immunopathological presentations. Approximatively 50% of DP-ANCA patients develop AAV, either as drug-induced or idiopathic forms, while the remaining 50%, characterized by pre-existing dysimmune conditions, demonstrates a remarkably low vasculitis risk. These findings underscore the complex nature of DP-ANCA, its variable impact on patient health, and the necessity for personalized diagnostic and management approaches in these cases.
引用
- Bettacchioli E, Foulquier JB, Chevet B, et al. Dual MPO/PR3 ANCA positivity and vasculitis: insights from a 7-cases study and an AI-powered literature review. Rheumatology (Oxford). 2024. PMID: 38552316. doi:10.1093/rheumatology/keae170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。